Serious IllnessNCT07009210
AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness
A study testing AI Assisted Personalized Legacy Program in people with Serious Illness and Existential Distress, run by Mayo Clinic at 2 sites in United States.
Trial summary
The purpose of this study is to determine if it is feasible and acceptable to recruit for and deliver the AI Assisted Personalized Legacy Program intervention to patients with serious illness. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Serious Illness, Existential Distress
- What is being tested?
- AI Assisted Personalized Legacy Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 2 sitesUnited States
- Study dates
- 11 Aug 2025to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- English fluency
- Provide informed consent
- Ability to complete questionnaire(s) by themselves or with assistance
Who cannot join
- Other psychological co-morbidities such as untreated schizophrenia, bipolar disease
- Recent suicide attempt or psychiatric illness severe enough that hospitalization has been necessary in last 6 months
- Active delirium
- Advanced dementia
- Participation in concurrent legacy offerings through the palliative care clinic
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Mayo Clinic
Phoenix, Arizona, 85054
Melissa Felt, 507-255-4162, felt.melissa@mayo.edu
Dept. of Medicine Research Hub, 507-266-1944, DOMResearchHub@mayo.edu
- Recruiting
Mayo Clinic
Rochester, Minnesota, 55905
Melissa Felt, 507-255-4162, felt.melissa@mayo.edu
Dept. of Medicine Research Hub, 507-266-1944, DOMResearchHub@mayo.edu
About this study
Official title: Feasibility and Acceptability of AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness
The purpose of this study is to determine if it is feasible and acceptable to recruit for and deliver the AI Assisted Personalized Legacy Program intervention to patients with serious illness.
Read the detailed description
This study is an investigator-initiated, multi-site Mayo Clinic prospective minimal risk pilot study to determine feasibility and acceptability of an AI Assisted Personalized Legacy Program. The AI Assisted Personalized Legacy Program intervention is a brief, individualized psychotherapy that aims to relieve psycho-emotional and existential distress and improve the experiences of patients whose lives are impacted by serious illness. This therapy offers patients an opportunity to reflect on their life with a trained facilitator and share their thoughts and memories with family and other people in their life. The sessions are recorded and transcribed. The interventionist will work with patients to edit the document and provide a final legacy document for patient to keep and give to loved ones.
- Conditions
- Serious Illness, Existential Distress
- Being tested
- AI Assisted Personalized Legacy Program
- Keywords
- Legacy Work
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI Assisted Personalized Legacy ProgramBehavioural
AI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work.
| Study group | Role | What they receive |
|---|---|---|
| AI Assisted Personalized Legacy Program | Experimental | Not described Receives: Behavioral: AI Assisted Personalized Legacy Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility Number
Study feasibility will be measured by the number of participants who enrolled and finished the study.
Measured: 2 years
Acceptability
Acceptability, as measured by the 7-item Was it Worth It (WIWI Questionnaire).The questions are answered as either "yes, no, or uncertain," overall perception of quality of life change, overall perception of study experience, one open-ended feedback question, and an option to talk with someone about concerns. Positive responses indicate acceptability. Results are reported as individual items.
Measured: 5-10 days post-delivery of the final legacy document
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start11 Aug 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Serious IllnessStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Deirdre R. Pachman, Mayo Clinic
- Investigators
- Deirdre Pachman, MD, Principal investigator, Mayo Clinic in RochesterMark Edwin, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07009210
- Sponsor's protocol ID
- 24-008402
- Status last verified
- Jun 2026
- First submitted
- 29 May 2025
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Acceptability of AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness
- ClinicalTrials.gov ID
- NCT07009210
- Acronym / sponsor ID
- 24-008402
- Conditions
- Serious Illness, Existential Distress
- Keywords
- Legacy Work
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 11 Aug 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if it is feasible and acceptable to recruit for and deliver the AI Assisted Personalized Legacy Program intervention to patients with serious illness.
Detailed description
This study is an investigator-initiated, multi-site Mayo Clinic prospective minimal risk pilot study to determine feasibility and acceptability of an AI Assisted Personalized Legacy Program. The AI Assisted Personalized Legacy Program intervention is a brief, individualized psychotherapy that aims to relieve psycho-emotional and existential distress and improve the experiences of patients whose lives are impacted by serious illness. This therapy offers patients an opportunity to reflect on their life with a trained facilitator and share their thoughts and memories with family and other people in their life. The sessions are recorded and transcribed. The interventionist will work with patients to edit the document and provide a final legacy document for patient to keep and give to loved ones.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AI Assisted Personalized Legacy Program | Experimental | Behavioral: AI Assisted Personalized Legacy Program |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥18 years
- English fluency
- Provide informed consent
- Ability to complete questionnaire(s) by themselves or with assistance
Key exclusion criteria (5 listed)
- Other psychological co-morbidities such as untreated schizophrenia, bipolar disease
- Recent suicide attempt or psychiatric illness severe enough that hospitalization has been necessary in last 6 months
- Active delirium
- Advanced dementia
- Participation in concurrent legacy offerings through the palliative care clinic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI Assisted Personalized Legacy ProgramAI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work. | Behavioural | AI Assisted Personalized Legacy Program |
Primary outcome
Feasibility Number
Time frame: 2 years
Study feasibility will be measured by the number of participants who enrolled and finished the study.
Acceptability
Time frame: 5-10 days post-delivery of the final legacy document
Acceptability, as measured by the 7-item Was it Worth It (WIWI Questionnaire).The questions are answered as either "yes, no, or uncertain," overall perception of quality of life change, overall perception of study experience, one open-ended feedback question, and an option to talk with someone about concerns. Positive responses indicate acceptability. Results are reported as individual items.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Serious Illness
Not yet recruiting
Financial Tools Access and Navigation (FinTAN)
Serious Mental Illness, Financial Hardship
Recruiting
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Schizophrenia Spectrum Disorders, Psychotic Affective Disorders
Not yet recruiting
Pilot Trial of Ambient Listening for Intensive Care Unit Family Meeting Summaries
Documentation of Serious Illness Communication for Critically Ill Patients
Enrolling by invitationPhase 3
Nudging Effective and Equitable Delivery of Specialty Palliative Care
Serious Illness, Palliative
Not yet recruitingObservational study
Community-Based Intensive Treatment (CBIT): Meeting the Complex Needs of Rural Adults With Serious Mental Illness
Severe Mental Illness, Hospitalizations Psychiatric
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Deirdre Pachman, MD principal investigator
Mayo Clinic in Rochester
Mark Edwin, MD principal investigator
Mayo Clinic
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI Assisted Personalized Legacy Program in people with Serious Illness and Existential Distress, run by Mayo Clinic at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Melissa Felt (507-255-4162, felt.melissa@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility Number (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.